AD-A108 661

NAVAL AIR DEVELOPMENT CENTER WARMINSTER PA AIRCRAFT --ETC F/G 6/1
STUDIES ON THE MECHANISM OF ACTION OF THE IN VITRO PGR(X) EFFEC--ETC(U)

UNCLASSIFIED


NADC-81229-60

NL

END
PART
THERE
I REL

END
PART
THERE
THERE
I REL

END
PART
THERE
THER



REPORT NO./NADC-81229-60



STUDIES ON THE MECHANISM OF ACTION OF THE IN VITRO PGB(x) EFFECT

II. REACTION MEDIUM COMPONENT REQUIREMENTS FOR PGEN EFFECT

H. W. Shmukler, Ph.D. Biochemistry Research Team Aircraft and Crew Systems Technology Directorate Naval Air Development Center Warminster, Pennsylvania 18974

M. G. Zawryt, B.A. E. Soffer, B.A. Hahnemann Medical College and Hospital Philadelphia, Pennsylvania 19102

1 September 1981

Phase Report Airtask No. F58527803 Work Unit No. EH810

APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED

Prepared for Office of Naval Research Department of the Navy Arlington, Virginia 22217

81 12 14 045

DEC 1 5 1981

OTIC FILE COPY

NOTICES

REPORT NUMBERING SYSTEM - The numbering of technical project reports issued by the Naval Air Development Center is arranged for specific identification purposes. Each number consists of the Center acronym, the calendar year in which the number was assigned, the sequence number of the report within the specific calendar year, and the official 2-digit correspondence code of the Command Office or the Functional Directorate responsible for the report. For example: Report No. NADC-78015-20 indicates the fifteenth Center report for the year 1978, and prepared by the Systems Directorate. The numerical codes are as follows:

CODE	OFFICE OR DIRECTORATE
00	Commander, Naval Air Development Center
01	Technical Director, Naval Air Development Center
02	Comptroller
10	Directorate Command Projects
20	Systems Directorate
30	Sensors & Avionics Technology Directorate
40	Communication & Navigation Technology Directorate
50	Software Computer Directorate
60	Aircraft & Crew Systems Technology Directorate
70	Planning Assessment Resources
80	Engineering Support Group

PRODUCT ENDORSEMENT - The discussion or instructions concerning commercial products herein do not constitute an endorsement by the Government nor do they convey or imply the license or right to use such products.

APPROVED BY:

R. WOODS

DATE:

11/20/81

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
NADC-81229-60	AD-A108	601
4. TITLE (and Subtitle)		5. Type of Report & Period Covered
Studies on the Mechanism of Action PGBx Effect. II. Reaction Medium	of the in vitro	Phase Report
Requirements for PGBx Effect		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s)		S. CONTRACT OR GRANT NUMBER(*)
H. W. Shmukler, M. G. Zawryt and E	. Soffer	N00014-8 W1007-0
9. PERFORMING ORGANIZATION NAME AND ADDRESS		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
Aircraft and Crew Systems Technolog	gy Directorate	Airtask No.~F58527803
Naval Air Development Center Warminster, PA 18974		Work Unit No. EH810
11. CONTROLLING OFFICE NAME AND ADDRESS		12. REPORT DATE
Office of Naval Research		1 Sep 1981
Department of the Navy Arlington, VA 22217		13. NUMBER OF PAGES
14. MONITORING AGENCY NAME & ADDRESS(II differen	from Controlling Office)	15. SECURITY CLASS. (of this report)
		UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report)	12 / 27	
	and the second	
	~	
Approved for public release; distri	Ibution unlimited	1
17. DISTRIBUTION STATEMENT (of the abetract entered	in Block 20, if different free	m Report)
18. SUPPLEMENTARY NOTES		
15. KEY WORDS (Continue on reverse side if necessary an	d identify by block number)	
PGBx		
Rat liver mitochondria		100000
Oxidative phosphorylation	•	•
	•	
The in vitro system for the assay of the PGB _X effect was investigated by exposing RLM to the individual components of the normal system, as well as to all possible binary mixtures of these constituents. The degree of degradation, as measured by the decrease in absorbance at $\lambda 525$ nm, was compared with the ability of RLM to carry out oxidative phosphorylation. The results indicate there is no correlation between the PGB _X effect and the effect of PGB _X on the swelling of RLM.		
there is no correlation between the	PGBx effect and	the effect of PGR on the

DD 1 JAN 73 1473 EDITION OF 1 NOV 68 IS OBSOLETE S/N 0102-LF-014-6601

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (Then Date Entered)

TABLE OF CONTENTS

	Page
LIST OF FIGURES	i
LIST OF TABLES	i
INTRODUCTION	1
METHODS AND MATERIAL	1
EXPERIMENTAL	2
DISCUSSION	7
REFERENCES	16

Accession For
NTIS CT .&I
DTIC TAB
Unenneumond
Ju. tiflestion
By -
Distribution!
Availability Codes
Avail and/or
Dist Special
1
1 1/2 1
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \

LIST OF FIGURES

Figure	<u>Title</u>	Page
la, 1b	The Phosphorylating Ability of RLM Exposed to Hypotonic Media as a Function of Time	9, 11
2a, 2b	The Effect of Added PGB on the	13, 15
3, 4, 5, 6	The Changes in Absorbance of $\lambda525\text{nm}$ for RLM Exposed to Various Hypotonic Media During Stage 1 and Stage 2 of the PGB Assay System	17, 19 21, 23
	LIST OF TABLES	
Table	<u>Title</u>	Page
I	The Composition of the Medium forthe Demonstration of the PGB Effect on Mitochondrial Oxidative Phosphorylation	2
II	Time Required to Deactivate RLM	3
III	The Effect of Various Degradation	6

INTRODUCTION

The possible use of PGB_X (1, 2, 3) as a therapeutic agent in the treatment of human ischemic diseases was suggested by the favorable results from only a few animal experiments (4, 5, 6, 7, 8, 9, 10). Obviously before any human trials may be undertaken much more animal testing must be completed, and in addition, certain basic information concerning the mechanism of action of this drug must be known. At this stage of our knowledge of PGB_X , the possibility of the successful elucidation of the in vivo mechanism of action appears remote. However, since the elucidation of the in vitro mechanism of PGB_X might reveal an insight as to the in vivo mechanism, studies have been underway to define the in vitro PGB_X effect.

In previous reports (11) it was shown that the $PGB_{\mathbf{X}}$ effect could only be demonstrated with isolated RLM exposed to the hypotonic conditions described by Polis et al (2). Since this "degradation" of RLM is a prerequisite for the demonstration of the $PGB_{\mathbf{X}}$ effect, the composition requirements of the degradation medium was studied in detail. This report describes the results of varying the composition of the $PGB_{\mathbf{X}}$ assay system on the demonstration of the $PGB_{\mathbf{X}}$ effect.

METHODS AND MATERIALS

 ${\rm PGB}_{\rm X}$ Type II prepared and assayed as described previously (2) was used in this study. The composition of the degradation stage was varied as indicated in the legends of the figures. In all cases the volume was 2.02 ml and the concentration of each component of the mixture was the same as that in the normal assay. At the end of the degradation stage, the constituents of the normal assay not added in the specific degradation test, were then added with the nucleotide mixture. The degradation time was determined by exposing the RLM to the specific degradation mixture for various times, usually 5-50 minutes, then adding the nucleotide mixture (stage 2) and allowing the reaction to proceed for 20 minutes. At this time the reaction was stopped by adding HClO4 and Pi concentration of the protein free filtrate was analysed as described previously (2, 3). In all cases 4.0mg RLM were used.

Note: Abbreviations used in this report are: RLM, rat liver mitochondria; Pi, inorganic phosphate; BSA, bovine serum albumin

The swelling and contraction of RLM exposed to the stages of the PGB_X assay were measured by absorbancy changes at $\lambda525\text{nm}$. The absorbancy was measured with a spectrophotometer (Bausch and Lomb Spectronic 100, Rochester, NY) and the output recorded on a 100 mv strip chart recorder (Laboratory Data Control, Riviera Beach, FL).

EXPERIMENTAL

In order to demonstrate the <u>in vitro</u> PGB_X effect on RLM oxidative phosphorylation, the RLM must first be deactivated by exposure to state 4 respiratory conditions (12). If the RLM were first exposed to state 3 respiratory conditions, no PGB_X effect was observed because the degree of phosphorylation was too high. It was of interest then, to study the effect of varying the composition of the degradation mixture in an attempt to ascertain those components involved directly in the PGB_X effect, and in this way possibly ascertain the mechanism of the <u>in vitro</u> PGB_X effect. As a reference point the degrading medium described by POLIS et al (2) and listed in Table I was first used in all the studies.

Order of Addition	Mitochondrial Degrading Medium	Reaction Mixture
Water	1.55 ml	1.55 ml
Phosphate Buffer pH 7.35	4.98 mM	4.55 mM
α-Ketoglutarate pH 7.35	14.93 mM	13.64 mM
MgS04	4.98 mM	4.55 mM
Aged Mitochondria	1.99 mg/ml	1.82 mg/ml
Sucrose*	5.97 mM	5.45 mM
EDTA*	0.010 mM	0.009 mM
AMP	***	2.27 mM
ADP		2.27 mM
KC1		45.45 mM
Bovine Serum Albumin		0.68 mg/ml

Total Volume: 2.20 ml Temperature: 28°

Degradation Time: 5-20 minutes Reaction Time: 20 minutes

*Added with mitochondria

To define the optimal conditions for the PGBx effect, RLM was exposed to solutions of the individual components of the normal degradation mixture as well as all possible mixtures of the three constituents. In addition, RLM was exposed to water only. The degree of RLM degradation was evaluated by measuring the residual ability of RLM to phosphorylate ADP under respiratory state 3 conditions. In preliminary experiments it was found that the residual RLM phosphorylation ability varied considerably depending upon the composition of the degradation medium. In order to compare the results of the various degradation media, a constant residual phosphorylation ability of 10% was chosen arbitrarily. The time to yield this level of RLM degradation was determined by measuring the residual phosphorylating ability as a function of time of exposure. When this data was plotted, the time to 10% phosphorylation could be interpolated. Figure 1 shows the residual phosphorylation as a function of degradation time for the normal system, water only, MgSO₄ only, phosphate buffer only and α -ketoglutarate only. Figure 1b shows the curves for normal system, a-ketoglutarate plus phosphate buffer, MgSO4 plus phosphate buffer, and MgSO4 plus a-ketoglutarate. The interpolated times to yield 10% phosphorylation by RLM exposed to the various media studied are listed in Table II.

TABLE II

Time Required to Deactivate RLM 90% When Exposed to Hypotonic Media

Medium Composition	Conc. (mM)	Time (minutes)
Normal System MgSO ₄ Phosphate α-ketoglutarate	4.98 4.98 14.93	10
Single Solutions Water MgSO4 Phosphate Buffer a-ketoglutarate	4.98 4.98 4.98 14.93	15 20 30 60
Binary Solutions a-ketoglutarate Phosphate	14.93 4.98	40
Phosphate MgS04	4.98 4.98	40
<pre>a-ketoglutarate MgS04</pre>	14.93 4.98	60

It is interesting to note that the degradation of RLM was the greatest when exposed to Polis's normal system, which was even greater than when RLM was degraded in the presence of H2O only. The medium that yielded the least degraded RLM was with α -ketoglutarate. When Pi was the degradation medium the degree of degradation was also at a low level. When binary mixtures of the three constituents were used, the RLM appeared to be more resistant. Again in the presence of a-ketoglutarate, even after 40 minutes, the RLM never were degraded to the 10% residual phosphorylation level. Using the degradation times listed in Table II for the specific medium, the effect of varying the PGB_X concentration from $2-36 \, \mu g/ml$ was measured and plotted. These results are shown in Figures 2A and 2B. A PGB_X effect was observed in all of the media tested, although the intensity and shape varied. In the case of the degradation media composed of individual constituents only, when phosphate buffer was used, the phosphorylation ability of the degraded RLM approached the level obtained with the normal system. When H_20 only, α -ketoglutarate only, and MgSO4 only was used as the degrading medium, a less intense PGBx effect was observed. In the case of the binary degradation media, when Pi was included in the mixture the PGB_X effect was approximately similar to that obtained with the normal system.

In an effort to correlate the effects of RLM degradation with the integrity of the RLM membrane, the swelling and contraction of RLM was measured during exposure to the degradation stage and to the reaction stage of the PGB_x effect²,³. The swelling and contraction were measured by following the absorbancy changes at $\lambda 525nm$. In Figure 3 the swelling and contraction of RLM exposed to the degradation media of H2O only, 0.3M sucrose only, the normal control system and the normal $PGB_{\mathbf{x}}$ system $(4.55 \mu g \ PGB_{\rm X}/ml)$ are shown. In the normal control system the RLM swell rapidly in the first three minutes and approach a minimum absorbance at the end of the degradation period. With the addition of the nucleotide mixture there is an immediate drop in absorbancy, probably caused by a dilution effect followed by a further slow drop in absorbance. In the presence of PGBx the absorbancy change in stage 1 is only changed slightly in that the final absorbance is higher than the control. However, upon the addition of the nucleotide mixture there is an immediate increase in absorbancy, indicating a contraction of RLM. This contraction is probably associated with the formation of ATP generated by the PGB_{X} treated system. In contrast, when 0.3M sucrose was the degradation medium, swelling did not occur either during the degradation stage or during the reaction stage. The drop in absorbancy after the addition of the nucleotides plus the remaining constituent of the assay system is the result of dilution. When water was the degrading medium the large drop in absorbancy

was too rapid to be recorded and only the final change was measured. Upon the addition of the remaining constituents, there was an immediate contraction resulting from the formation of ATP followed by a slow decrease in absorbance.

Figure 4 shows the swelling and contraction of RLM exposed to αketoglutarate alone, phosphate buffer alone and MgSO4 alone. When the RLM was exposed to a-ketoglutarate alone there were only minor changes in absorbance during stages 1 and 2. In the presence of inorganic phosphate there was a gradual, continuous swelling during stage l with an immediate contraction during stage 2 which was maintained during the course of stage 2. In the presence of MgSO4 alone, during stage 1 the immediate swelling was too fast to be recorded. The swelling then leveled off during the remainder of stage 1. During stage 2 there was an immediate contraction, followed by a slow swelling of the RLM. The swelling and contraction of the RLM exposed to the binary mixtures are shown in Figure 5. The swelling and contraction profiles of RLM in the presence of MgSO4 and Pi, and in the presence of a-ketoglutarate and Pi were similar to that observed with MgSO4 alone (Figure 4). The swelling and contraction profile of RLM in the presence of a-ketoglutarate plus Pi was characterized by a slow swelling during stage 1 that leveled off after about three minutes and during stage 2, only a slight contraction was observed which remained approximately constant.

In addition to the degradation studies of RLM in the presence of the normal PGB_{x} stage 1 constituents, similar studies were also carried out using the normal stage 2 constituents. Figure 6 shows that in the presence of KC1 only, RLM show an immediate contraction followed by no change in absorbance during stage 1; however upon the addition of stage 2 reactants there was an immediate and slow contraction that leveled off after several minutes. In contrast when RLM were exposed to KC1 plus PGB_{x} , the stage 1 absorbance profile was similar; however in stage 2 the swelling was followed by a contraction. When the AMP and ADP mixture was the medium in stage 1, there was a slow swelling of RLM followed by an immediate contraction upon the addition of the stage 2 components. When BSA only was the stage 1 medium the swelling and contraction profile was similar to that of $H_{2}O$ only, except that the swelling and resultant contraction were at a lower level.

In an attempt to relate the PGB_X effect with possible changes in RLM morphology, the degree of swelling of RLM and the phosphorylating ability after exposure to the various degradation media were summarized in Table III.

TABLE III

The Effect of Various Degradation Media on the Swelling and Phosphorylating Ability of RLM

Composition of Degradation Medium ¹	Degree of Swelling $(\Delta A525nm/m1)^2$	Pi Esterified (mM)
Normal System Control	-0.406	0.18
Normal System + PGB_{x} (4.95µg/ml)	-0.356	2.73
H ₂ 0 only	-0.441	0.69
MgSO ₄	-0.262	1.38
Pi only	-0.366	2.63
α-ketoglutarate only	-0.144	2.11
MgSO ₄ plus Pi	-0.262	2.76
KCl only	-0.220	2.13
KC1 + MgSO ₄	-0.025	2.53
AMP + ADP	-0.366	1.32
BSA only	-0.599	1.81

 $^{^{\}rm 1}$ Total volume of degradation mixture was 2.02 ml, and contained 4.0mg RLM; the concentration of each constituent was that used in the normal system.

 $^{^2}$ $^\Delta$ ^A525nm was calculated by subtracting the ^A525nm of each test after 10 minutes and subtracting this value from that found for ^A525nm for 4.0mg RLM in 2.02 ml 0.3M sucrose. Negative values indicate swelling.

From these data there appeared to be no relationship between the morphological integrity of the RLM and its ability to phosphorylate. Those conditions that resulted in the least ability of the RLM to phosphorylate, namely $\rm H_2O$ only and the normal control system, showed a high degree of swelling, although not as high as that shown with BSA only. In this latter system the ability of the RLM to carry out phosphorylation was reduced only about 50%. Those media that resulted in the least swelling of RLM, e.g. KCl only and KCl plus MgSO4, only caused a 30% decrease in phosphorylating ability.

DISCUSSION

The results of this study show that the hypotonic medium used by Polis $\underline{\text{et al}^{\,2}},^3$ to degrade RLM is the optimum medium to demonstrate the PGBx effect. The omission of any one constituent, or the use of only one constituent, results in the RLM not being sufficiently degraded to show the PGBx effect. However by modifying the experimental conditions so that the RLM are degraded sufficiently, i.e. 10% residual phosphorylating ability, then in all the media studied a PGBx effect was observed.

The results also point out that the ability of RLM to phosphorylate is not necessarily dependent upon the degree of morphological swelling. The addition of PGB_X to the normal system only induces a minor change in swelling yet a tremendous improvement in phosphorylating ability. When RLM were exposed to media that induced only a minimal swelling, the concomitant phosphorylating ability was not maximal. On the other end of the scale, the medium that induced the greatest swelling, BSA only, still yielded RLM that gave a relatively high phosphorylation activity.

In previous studies it was observed that RLM exposed to the normal hypotonic medium for the required time, when then treated with PGB $_{\rm X}$, showed no improvement in swelling nor in phosphorylating ability. From this it was concluded that PGB $_{\rm X}$ reacts with RLM to protect them from hypotonic swelling. From the results of this study the above explanation appears too simplistic. Although PGB $_{\rm X}$ must bind to the RLM, it does not inhibit swelling and therefore must perform some other function, which unfortunately is unknown at this time.

Figure (1a): The phosphorylating ability of RLM exposed to hypotonic media as a function of time. RLM (4.0mg) were added to the media at a final volume of 2.02 ml. At the end of each degradation. Time the nucleotide mixture plus the components of the normal system omitted in each test were then added and the reaction allowed to proceed for 20 minutes. The concentration of the components alone and in the binary mixtures was that listed in Table I. At the end of this time the solution was deproteinized by the addition of HClO and the Pi analysed as described previously (2.3). Legend for curves: ., normal system; +, H_2 0 only; , $MgSO_4$ only; 0, phosphate buffer only; and Δ 0, c-ketoglutarate only.




Figure la - The Phosphorylating Ability of RLM Exposed to Hypotonic Media as a Function of Time

.

Figure (1b): Legend for curves: ., normal system; Δ , α -keto-glutarate and phosphate buffer; 0, phosphate buffer and MgSO₄; and α -ketoglutarate and MgSO₄.




Figure 1b - The Phosphorylating Ability of RLM Exposed to Hypotonic Media as a Function of Time

Figure (2a): The effect of added PGB on the phosphorylating ability of RLM after exposure to various hypotonic media. RLM (4.0mg) were added to the hypotonic containing various amounts of PGB. The final volume of the degradation media was 2.02 ml. The degradation times used were calculated to yield less than 10% residual phosphorylation by the degraded RLM (Table II). After the addition of stage 2 reactants the Pi remaining was analysed as described previously (2,3). Legend for curves: ., normal system; +, II_2 0 only; , $MgSO_4$ only; 0, phosphate buffer only; and Δ , α -ketoglutarate only.




Figure 2a - The Effect of Added PGB on the Phosphorylating Ability of RIM After Exposure to Various Hypotonic Media

Figure (2b): Legend for curves: ., normal system; 0, MgSO and phosphate buffer; , $\alpha\text{-ketoglutarate}$ and MgSO4; and Δ , $\alpha\text{-ketoglutarate}$ and phosphate buffer




Figure (3): The changes in absorbance at $\lambda525nm$ for RLM exposed to various hypotonic media during stage 1 and stage 2 of the PGB assay system. (See Table I for the concentration of the reagents used). RLM (4.0mg) were added to hypotonic media (total volume, 2.02 ml) was the $\lambda525nm$ recorded as a function of time. After 13 minutes stage 2 geactants were added as indicated by the break in the curves, and the $\lambda525nm$ recorded for an additional 13 minutes. Legend for curves:

Curves:

O, H₂O only; and ×, 0.3M sucrose containing $5\times10^{-4}M$ EDTA.

1 6 W. 1. 14




Figure 3 - The Changes in Absorbance of $\lambda525nm$ for RLM Exposed to Various Hypotonic Media During Stage 1 and Stage 2 of the PGB _Assay System

ł

0.5

(mm 252 A) IDMAGNOSISA

5.

Figure (4): See Figure 3 for details. Legend for curves: ---, a-ketoglutarate only; , phosphate buffer only; x, MgSO₄ only.




Figure 4 - The Changes in Absorbance of $\lambda 525nm$ for RLM Exposed to Various Hypotonic Media During Stage 1 and Stage 2 of the PGB _Assay System

Figure (5): See Figure 3 for details. Legend for curves: a-ketoglutarate and phosphate buffer; ---, $MgSO_4$ and and phosphate buffer.




Figure 5 - The Changes in Absorbance of \1525nm for RLM Exposed to Various Hypotonic Media During Stage 1 and Stage 2 of the PGB Assay System

Figure (6): See Figure 3 for details. Legend for curves: $\overline{KC1}$; ---, $\overline{KC1}$ and \overline{PGB}_X (10µg); ×, nucleotide; and 0, BSA.




Figure 6 - The Changes in Absorbance of $\lambda 525 nm$ for RLM Exposed to Various Hypotonic Media During Stage 1 and Stage 2 of the PGB Assay System

REFERENCES

- Polis, B. D., A. M. Grandizio, E. Polis: Some <u>in vitro</u> and <u>in vivo</u> Effects of a New Prostaglandin Derivative. <u>Neurohumoral and Metabolic Aspects of Injury</u>. <u>Adv. in Exper. Med. and Biol.</u>, Plenum Press, New York 33:213-220 (1973).
- 2. Polis, B. D., S. F. Kwong, E. Polis and G. Nelson: Studies on PGB_X : A Polymeric Derivative of Prostaglandin B1: I Synthesis and Purification of PGB_X . Report No. NADC-78235-60 (1978).
- Polis, B. D., E. Polis and S. F. Kwong: Protection and Reactivation of Oxidative Phosphorylation in Mitochondria by a Stable Free-Radical Prostaglandin Polymer (PGB_X). Proc. Natl. Acad. Sci., 76:1598-1602 (1979).
- 4. Angelakos, E. T., B. D. Polis and R. L. Riley: Recovery After Coronary Ligation and Fibrillation in Primates Treated with a Prostaglandin Derivative. 47th Scientific Sessions American Heart Association, Abstracts, Dallas, Texas (1974).
- 5. Angelakos, E. T., B. D. Polis and R. L. Riley: Protection by a Prostaglandin Derivative from Mortality after Coronary Ligation from Ventricular Fibrillation in Primates. 6th International Congress of Pharmacology Abstracts, Helsinki, Finland (1975).
- 6. Angelakos, E. T., R. L. Riley and B. D. Polis: Recovery of Monkeys from Cardiogenic Shock After Myocardial Infarction with Ventricular Fibrillation. Effects of PGB_X Report No. NADC-77308-60 (1977).
- Kolata, R. J.: The Effect of PGB_x on Neurological Recovery from Cerebral Ischemia in Rabbits. <u>Masters Thesis</u>, <u>Univ. of Penna</u>. Veterinary School (1977).
- 8. Kolata, R. J. and B. D. Polis: Facilitation of Recovery from Ischemic Brain Damage in Rabbits by Polymeric Prostaglandin PGB_X , a Mitochondrial Protective Agent. Physiol. Chem. and Physics 12, 551 (1980).
- Yamazaki, H., M. M. Bodenheimer, V. S. Banka, J. Lewandowski and R. H. Helfant: The Effect of a New Prostaglandin (PGB_X) on Length-tension Relationship Following Partial Coronary Occlusion and Reperfusion. <u>Amer. Heart Assn.</u>, <u>Abstracts 51st Scientific Session</u>, Dallas, Texas, (1978).

- 10. Moss, G., T. Magliochetti and R. Quarmby: Immediate Restoration of Central Nervous System Autonomic Cardio-pulmonary Control: Survival of "Lethal" Cerebral Hypoxia by Treatment with PGB_X. Surgical Forum, 21:513, (1978).
- 11. Shmukler, H. W., M. G. Zawryt and E. Soffer: Studies on the Mechanism of Action of the in vitro PGB_X Effect: I. (In preparation).
- 12. Chance, B. and G. R. Williams: Respiratory Enzymes in Oxidative Phosphory-lation III Steady State. J. Biol. Chem. 217, 409 (1955).

DISTRIBUTION LIST

REPORT NO. NADC-81229-60

CONTRACT NO. N00014-81-W1007-0

	No. of Copies
Defense Technical Information Center, Building 5,	
Cameron Station, Alexandria, VA 22314 Naval Research Laboratory, Attn: Technical Information	. 12
Division (Code 2627), Washington, DC 20375	. 6
Office of Naval Research, Attn: Code 102IP (ONRL DOC), 800 N. Quincy Street, Arlington, VA 22217	. 6
Arlington, VA 22217	. 3
Arlington, VA 22217	. 1
Section D, 666 Summer St., Boston, MA 02210 Office of Naval Research, Branch Office, 536 S. Clark St.,	. 2
Chicago, IL 60605	. 1 .
Pasadena, CA 91106	. 1
Medical Center, Bethesda, MD. 20014	. 1
Washington, DC 20375	. 1
National Naval Medical Center, Bethesda, MD 20014 Naval Medical Research Unit No. 2, Box 14, APO,	. 2
San Francisco, CA 96263	. 1
Naval Medical Research Unit No. 3, FPO, NY 09527	
New London, Groton, CT 06342	. 1
Library, Naval Aerospace Medical Center, Pensacola, FL 32512	. 1
Center, Oakland, CA 94625	. 1
NC 27709	. 1
Sciences, Bolling Air Force Base, Washington, DC 20332 Army Medical Research & Development Command, Forrestal	. 1
Building, Washington, DC 20314	. 1
Far East, APO, San Francisco, CA 96328	. 1

END DATE FILMED

DTIC